OCAL Financial tops 1,250 funded vehicle deals to date
Bitget2026/10/06 13:43OCAL Financial reported more than 1,250 funded vehicle deals to date across British Columbia and Alberta. Revenue rose to about $6.48 million in fiscal 2025 from about $5.8 million in fiscal 2024, an increase of about 11.72%. Management metrics for the trailing 12 months showed about 98% of funded deals included a warranty or protection product. Median cycle times ran about seven days from lead to signed, then about three to four days from signed to funded. Repeat and referral customers accounted for roughly 17.6% of funded deals; the company outlined plans to enter Ontario. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OCAL Financial Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610060942NEWSFILECNPR____20261006_317641_1) on October 06, 2026, and is solely responsible for the information contained therein.
- OCAL Financial reported more than 1,250 funded vehicle deals to date across British Columbia and Alberta.
- Revenue rose to about $6.48 million in fiscal 2025 from about $5.8 million in fiscal 2024, an increase of about 11.72%.
- Management metrics for the trailing 12 months showed about 98% of funded deals included a warranty or protection product.
- Median cycle times ran about seven days from lead to signed, then about three to four days from signed to funded.
- Repeat and referral customers accounted for roughly 17.6% of funded deals; the company outlined plans to enter Ontario.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300